Heidi Vorac
Family · Geneseo, ILNPI 1669874608
Payments from drug & device makers
Across 117 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$491
- AbbVie$285
- Pfizer$236
- Lilly USA, LLC$157
- Almatica Pharma LLC$97
- Eisai Inc.$90
- plus $704 from 17 others
What the payments were for
- Food & beverage$2,061100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $491 |
| AbbVie | 14 | $285 |
| Pfizer | 14 | $236 |
| Lilly USA, LLC | 10 | $157 |
| Almatica Pharma LLC | 6 | $97 |
| Eisai Inc. | 4 | $90 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $88 |
| Idorsia Pharmaceuticals US Inc | 5 | $83 |
| Novo Nordisk | 5 | $81 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $66 |
| Exact Sciences | 4 | $62 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Amgen | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 3 | $30 |
| Novartis | 2 | $30 |
| Corium, LLC | 1 | $23 |
| Organon | 1 | $17 |
| Medtronic | 1 | $16 |
| Abbott | 1 | $13 |
| Genentech USA, Inc. | 1 | $8 |
How this compares
$2,061 in reported general payments places this provider in the 85th percentile of 4,941 family providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 47 | $58,458 |
| EliquisApixaban | 78 | $50,961 |
| MounjaroTirzepatide | 23 | $27,511 |
| OzempicSemaglutide | 16 | $22,330 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $14,599 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $12,221 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,824 |
| Levothyroxine Sodium | 355 | $2,733 |
| Potassium Chloride | 86 | $2,240 |
| Gabapentin | 139 | $1,999 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $1,865 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $1,731 |
| Tramadol Hcl | 133 | $1,711 |
| Atorvastatin Calcium | 239 | $1,613 |
| Omeprazole | 131 | $1,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $236 | $50,96178 claims |
| Lilly USA, LLCMounjaro | $157 | $27,51123 claims |
| Novo NordiskOzempic | $81 | $22,33016 claims |
| AbbVieSynthroid | $285 | $1,23415 claims |
| Almatica Pharma LLCSertraline Hcl | $97 | $908122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,941 family providers in Illinois.
Other family in Geneseo
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Brooke KennardBloomington$208K
- Amy BrownellElk Grove Village$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.